$166.14
-0.44[-0.26%]
At close: Apr 29
$166.14
0[0.00%]
After Hours: 4:00PM EDT
Repligen
(NASDAQ:RGEN)Latest News for Repligen Stock (NASDAQ:RGEN)
Repligen Stock (NASDAQ: RGEN)
Categories: All
Tuesday, April 23, 2024
Monday, March 25, 2024
Wednesday, February 21, 2024
- What's Going On With Life Science-Focused Repligen Stock Today?Vandana Singh - Feb 21, 2024, 10:25AM
- Repligen shares are trading lower after the company issued weak guidance for 2024.Benzinga Newsdesk - Feb 21, 2024, 8:17AM
- Repligen Expects Fiscal Year 2024 Adjusted EPS Of $1.42 - $1.49 Versus Consensus Of $1.77Benzinga Newsdesk - Feb 21, 2024, 7:36AM
- Repligen Expects Fiscal Year 2024 Revenue Of $620M-$650M Versus Consensus Of $660.68MBenzinga Newsdesk - Feb 21, 2024, 7:36AM
- Repligen Q4 Adjusted EPS $0.33, Inline, Sales $155.74M Beat $155.39M EstimateBenzinga Newsdesk - Feb 21, 2024, 7:31AM
- Earnings Scheduled For February 21, 2024Benzinga Insights - Feb 21, 2024, 5:09AM
Thursday, February 15, 2024
Friday, January 26, 2024
Wednesday, December 20, 2023
Thursday, December 07, 2023
Monday, December 04, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
Wednesday, November 01, 2023
- Stifel Maintains Buy on Repligen, Lowers Price Target to $165Benzinga Newsdesk - Nov 1, 2023, 3:38PM
- UBS Maintains Buy on Repligen, Lowers Price Target to $170Benzinga Newsdesk - Nov 1, 2023, 3:12PM
- Keybanc Maintains Overweight Rating for Repligen: Here's What You Need To KnowBenzinga Insights - Nov 1, 2023, 1:00PM
- RBC Capital Maintains Outperform on Repligen, Lowers Price Target to $200Benzinga Newsdesk - Nov 1, 2023, 12:52PM
- Keybanc Maintains Overweight on Repligen, Lowers Price Target to $210Benzinga Newsdesk - Nov 1, 2023, 5:41AM
Tuesday, October 31, 2023
- Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 31, 2023, 1:36PM
- Repligen shares are trading higher after the company reported better-than-expected Q3 results.Benzinga Newsdesk - Oct 31, 2023, 12:57PM
- Repligen's Strong Q3 Recovery: CEO Says Pharma Orders Rebound, Analytics Business GrowsVandana Singh - Oct 31, 2023, 12:32PM
- Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On TuesdayLisa Levin - Oct 31, 2023, 12:04PM
- Repligen Expects FY23 Adjusted EPS Of $1.70-$1.76 Versus Prior Guidance Of $1.72-$1.80 And Consensus Of $1.74Benzinga Newsdesk - Oct 31, 2023, 7:38AM
- Repligen Expects FY23 Revenues Of $635M-$645M Versus Prior Guidance Of $635M-$665M And Consensus Of $644.53MBenzinga Newsdesk - Oct 31, 2023, 7:38AM
- Repligen Q3 Adjusted EPS $0.23 Beats $0.17 Estimate, Sales $141.19M Beat $140.64M EstimateBenzinga Newsdesk - Oct 31, 2023, 7:33AM
- Earnings Scheduled For October 31, 2023Benzinga Insights - Oct 31, 2023, 5:44AM
Monday, October 30, 2023
Wednesday, October 25, 2023
Tuesday, October 17, 2023
Monday, October 02, 2023
Tuesday, September 26, 2023
- Life Sciences Player Repligen's Strategic European Acquisition - What It Means for InvestorsVandana Singh - Sep 26, 2023, 3:07PM
- Repligen Agrees To Acquire Metenova Expanding Repligen's Fluid Management Portfolio, Complements Single-use Bag Offering, Deal Terms Were Not DisclosedBenzinga Newsdesk - Sep 26, 2023, 7:37AM
Tuesday, September 12, 2023
Friday, September 08, 2023
Wednesday, September 06, 2023
Thursday, August 17, 2023
Thursday, August 03, 2023
- Craig-Hallum Maintains Buy on Repligen, Lowers Price Target to $200Benzinga Newsdesk - Aug 3, 2023, 3:26PM
- RBC Capital Maintains Outperform on Repligen, Raises Price Target to $195Benzinga Newsdesk - Aug 3, 2023, 10:30AM
- Stephens & Co. Maintains Overweight on Repligen, Raises Price Target to $200Benzinga Newsdesk - Aug 3, 2023, 9:07AM